Knight Therapeutics Inc
TSX:GUD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
K
|
Knight Therapeutics Inc
TSX:GUD
|
CA |
|
X
|
XMReality AB (publ)
STO:XMR
|
SE |
|
Mhp Se
LSE:MHPC
|
UA |
|
D
|
Dexin China Holdings Company Ltd
HKEX:2019
|
CN |
|
Summit Therapeutics Inc
NASDAQ:SMMT
|
US |
Multiples-Based Value
The Multiples-Based Value of one GUD stock under the Base Case scenario is hidden CAD. Compared to the current market price of 7.08 CAD, Knight Therapeutics Inc is hidden .
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Multiples Across Competitors
GUD Competitors Multiples
Knight Therapeutics Inc Competitors
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
K
|
Knight Therapeutics Inc
TSX:GUD
|
702.3m CAD | 1.6 | -130.7 | 10.5 | 126 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
829.8B USD | 12.7 | 40.2 | 27.2 | 29 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
579B USD | 6.1 | 21.6 | 15 | 18.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4 | 19.3 | 11.5 | 12.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
296B USD | 4.6 | 16.2 | 10 | 12.2 | |
| CH |
|
Novartis AG
SIX:NOVN
|
229.3B CHF | 5.2 | 21.1 | 13 | 16.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
214.5B GBP | 5.1 | 29.1 | 16.1 | 22.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
237.1B USD | 102.3 | -81.1 | 375.3 | 941.3 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1T DKK | 3.3 | 9.8 | 7.3 | 8.6 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.7B USD | 2.5 | 19.8 | 7.6 | 10.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
117.8B USD | 2.4 | 16.7 | 7.1 | 8.7 |